Other languages Oragenics, Inc.

Equities

OGEN

US6840235005

Market Closed - Nyse Other stock markets 04:10:00 2024-04-25 pm EDT			5-day change	1st Jan Change
1.06 ^USD	-2.75%		-6.19%	-81.16%

Apr. 12	North American Morning Briefing : Big Banks Kick -2-	DJ
Mar. 29	Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 29
Oragenics Appoints James Kelly MD as Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion	Mar. 18
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion	Mar. 05
Top Midday Decliners	Feb. 28
Oragenics CEO Kimberly Murphy Steps Down, Board Chair to Serve as Interim Executive Chair	Feb. 13
Oragenics, Inc. Announces Leadership Transition	Feb. 12
Oragenics, Inc. Announces CEO Changes	Feb. 12
Oragenics, Inc. Prepares for Phase II Clinical Trials to Treat Concussion	Feb. 05
Oragenics, Inc. Announces Management Changes	Dec. 29
Oragenics, Inc. completed the acquisition of Assets related to proprietary neurological drug therapies and technologies of Odyssey Health, Inc.	Dec. 27
Oragenics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
Oragenics Announces Directorate Appointments	23-10-18
Oragenics, Inc. Announces Board Appointments	23-10-05
Aktien New York Ausblick: Träger Start in den Oktober erwartet	23-10-02
MORNING BRIEFING - USA/Asien	23-10-02
Oragenics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Oragenics to Develop Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate	23-06-05
Oragenics, Inc. Announces the Award of Grant from CQDM for the Collaborative Development of a Variant-Agnostic COVID-19 Protein Subunit Vaccine Candidate	23-06-05
Oragenics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12
Oragenics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-04-17

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Oragenics, Inc.

Equities

OGEN

US6840235005

Other languages

Filters